What Establishment Labs (ESTA) Said on Its Q3 Earnings Call

Establishment Labs NASDAQ: ESTA reported third-quarter revenue growth of 33.9% year over year to $72 million, driven by U.S. market-share gains and expansion across international markets, while the company generated positive free cash flow for the first time in its history.

MarketBeat • 11 hours ago

Establishment Labs Holdings Inc. (ESTA) Q3 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q3 2026 Earnings Call Transcript

Seeking Alpha • 8 hours ago

Establishment Labs® Reports Third Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2026. Third Quarter Business Highlights Announced a new supply agreement with NuSil to support long-term manufacturing capacity and future growth. Received FDA approval for additional smaller Motiva implant.

Business Wire • 13 hours ago

Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.38 per share a year ago.

Zacks Investment Research • 9 hours ago

Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?

Establishment Labs (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2026

Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2026, before the market opens on Thursday, October 29, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results.To participate in the conference call, Dial: (+1) 877-407-8037 (US.

Business Wire • Oct 19, 2026

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States. The approval adds 28 new sizes to the Motiva U.S. portfolio, including implants as sm.

Business Wire • Oct 5, 2026

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements.

Business Wire • Sep 21, 2026

Establishment Labs: Procedure Economics Strengthens The Bull Case

Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.

Seeking Alpha • Sep 9, 2026

Baron Discovery Fund Q2 2026 Portfolio Activity

We see a long runway for growth as Samsara expands in existing accounts and wins new logos. We believe Shake Shack is one of the most compelling growth stories in restaurants today, with a differentiated brand, improving unit economics, and an accelerating unit growth algorithm. We initiated a position in Rubrik, a subscription software company focused on automating backup, storage, and recovery of corporate data, as well as creating resilience to cyberattacks on that data.

Seeking Alpha • Aug 28, 2026